Use of Tissue Plasminogen Activator (rt-PA) in Young Children With Cancer and Dysfunctional Central Venous Catheters
Authors:
- Louis CheslerLCLouis Chesler
- James H. FeusnerJFJames H. Feusner
- 1 November 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 24 (8) , 653-656
Abstract
To determine the efficacy and safety of low, nonescalating dose tissue plasminogen activator (rt-PA) in restoring the patency of occluded central venous access devices (CVCs) in children with cancer who weigh less than 30 kg. A single-center review of the use of rt-PA (0.5 mg indwelling for 30 minutes in the CVC) was conducted in 42 cancer patients with large bore central venous access devices implanted over a 2-year period. All patients weighed less than 30 kg. None had been previously treated with a thrombolytic agent. The efficacy for restoring function to CVCs was measured and correlated with patient age, weight and CVC lumen size. Propensity to rethrombose following an initial occlusion and treatment was also determined. Of 235 doses of rt-PA administered in a 2-year period, 55 doses administered to 42 patients met the eligibility criteria as outlined. Twenty-nine patients (69%) had function restored with a single dose; 8 patients (19%) required 2 doses, and 5 patients (12%) failed 2 doses; for an overall success rate of 88%. No significant adverse events occurred. Of the 37 cleared CVCs, 14 (38%) reoccluded within 1 month. A higher proportion of patients initially treated with one rt-PA (71%) experienced another CVC dysfunction within 1 month, compared with 29% CVC dysfunction in those requiring >1 dose. This article describes the use of rt-PA (0.5 mg, without dose escalation) to lyse CVC-associated thrombi specifically in small children with cancer, a patient population in which it is particularly desirable to minimize the degree of fibrinolysis. One dose of 0.5 mg rt-PA, with an additional dose if necessary, is as safe and effective as previously reported escalating dose regimens for CVC clot lysis. There is no statistically significant correlation of treatment failure with patient age, weight, or catheter lumen size, and no significant propensity for rapid rethrombosis following a single dysfunction and treatment. Patients initially treated with a single dose of rt-PA appear to have more subsequent dysfunctions in the month after treatment, an observation that warrants further study.Keywords
This publication has 8 references indexed in Scilit:
- A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunctionAmerican Journal of Kidney Diseases, 2002
- Recombinant tissue plasminogen activator in the treatment of central venous catheter occlusion in childrenThe Journal of Pediatrics, 2001
- The use of alteplase to restore patency of central venous lines in pediatric patients: A cohort studyThe Journal of Pediatrics, 2001
- Activity and dosage of alteplase dilution for clearing occlusions of venous-access devicesAmerican Journal of Health-System Pharmacy, 2000
- Tissue plasminogen activator and obstructed central venous cathetersMedical and Pediatric Oncology, 1998
- Guidelines for antithrombotic therapy in pediatric patientsThe Journal of Pediatrics, 1998
- Urokinase versus Recombinant Tissue Plasminogen Activator in Thrombosed Central Venous Catheters:Thrombosis and Haemostasis, 1994
- Investigational Use of Tissue Plasminogen Activator (t‐PA) for Occluded Central Venous CathetersJournal of Parenteral and Enteral Nutrition, 1990